Company Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Why Investors Should Care
Trades at a P/E of 25.0, below the sector median of 25.9.
Offers a dividend yield of 2.86%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $44.33B (+5.7% YoY); net profit $6.52B.
- Trailing 12 Months Year-on-year growth — revenue +7.8%, earnings -19.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.5%, profit CAGR -2.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.51% |
| 1 Year: | 7.80% |
Compounded Profit Growth
| 5 Years: | -2.01% |
| 1 Year: | -19.70% |
Stock Price Performance
| 1 Year: | -31.01% |
| 6 Months: | -27.56% |
| 3 Months: | -11.10% |
| 1 Month: | +1.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)42.98 · Neutral
P/E of 25.01 is below the sector median of 25.88 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 2.86%.
- Generates positive free cash flow.
CONS
- Earnings shrank at -2.0% CAGR over 5 years.
- Trading 33.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ABT Abbott Laboratories SPX | 89.27 | 25.01 | $155.49B | 2.86% | 12.76% | 12.33% | 0.51% | -2.01% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 6.33B | 6.64B | 6.83B | 7.59B | 7.39B | 7.77B | 7.66B | 7.76B | 7.54B | 7.98B | 8.08B | 8.31B | 7.73B | 7.33B | 8.85B | 10.46B | 10.22B | 10.93B | 11.89B | 11.26B | 10.41B | 9.75B | 9.98B | 10.14B | 9.96B | 10.38B | 10.63B | 10.36B | 11.14B | 11.37B | 11.46B | 11.16B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.47B | 4.85B | 5.08B | 4.92B | 4.89B |
| Gross Profit | 2.66B | 2.80B | 2.76B | 2.84B | 2.60B | 2.90B | 2.88B | 2.90B | 2.75B | 3.06B | 3.45B | 3.75B | 3.74B | 3.92B | 3.95B | 4.09B | 3.89B | 4.22B | 4.23B | 4.40B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.89B | 6.29B | 6.29B | 6.54B | 6.27B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.20B | 4.24B | 4.24B | 4.29B | 4.93B |
| Operating Income | 610.00M | 729.00M | 713.00M | - | 524.00M | 816.00M | 897.00M | - | -242.00M | 386.00M | 769.00M | - | 608.00M | 882.00M | 995.00M | - | 739.00M | 1.21B | 1.20B | - | 758.00M | 672.00M | 1.50B | 2.11B | 1.39B | 2.55B | 2.91B | 2.38B | 1.77B | 1.51B | 1.54B | 1.65B | 1.39B | 1.67B | 1.86B | 1.69B | 2.05B | 2.06B | 2.25B | 1.34B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.67B | 3.05B | 3.09B | 3.27B | 2.43B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 131.00M | 121.00M | 121.00M | 120.00M | 174.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.78B | 2.15B | 2.18B | 2.36B | 1.45B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 453.00M | 371.00M | 536.00M | 582.00M | 372.00M |
| Net Income | 2.29B | 784.00M | 580.00M | 767.00M | 316.00M | 615.00M | -329.00M | 798.00M | 419.00M | 283.00M | 603.00M | -828.00M | 418.00M | 733.00M | 563.00M | 654.00M | 672.00M | 1.01B | 960.00M | 1.05B | 564.00M | 537.00M | 1.23B | 1.79B | 1.19B | 2.10B | 2.45B | 2.02B | 1.44B | 1.32B | 1.38B | 1.44B | 1.23B | 1.30B | 1.65B | 1.32B | 1.78B | 1.64B | 1.78B | 1.08B |
| Diluted EPS | 1.51 | 0.52 | 0.38 | 0.51 | 0.21 | 0.41 | -0.22 | 0.53 | 0.24 | 0.16 | 0.34 | -0.48 | 0.23 | 0.41 | 0.32 | 0.37 | 0.38 | 0.56 | 0.53 | 0.59 | 0.31 | 0.30 | 0.69 | 1.00 | 0.66 | 1.17 | 1.37 | 1.14 | 0.81 | 0.75 | 0.78 | 0.82 | 0.70 | 0.74 | 0.94 | 0.76 | 1.01 | 0.94 | 1.01 | 0.61 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | 589.00M | 575.00M | 574.00M | - | 672.00M | 577.00M | 596.00M | - | 578.00M | 564.00M | 580.00M | 654.00M | 654.00M | 672.00M | 697.00M | 684.00M | 782.00M | 654.00M | 715.00M | 672.00M | 684.00M | 698.00M | 713.00M | 716.00M | 725.00M | 766.00M | - | 767.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.91B | 29.53B | 30.76B | 35.17B | 21.41B | 19.05B | 19.66B | 20.25B | 20.41B | 20.85B | 27.39B | 30.58B | 31.90B | 34.61B | - | 43.65B | 40.11B | 41.95B | 44.33B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.14B | 17.98B | 18.71B | 19.32B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.51B | 22.13B | 23.24B | 25.01B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.15B | 15.66B | 16.42B | 16.96B |
| Operating Income | 4.58B | 5.69B | 6.24B | 6.09B | 1.63B | 1.36B | 2.13B | 2.60B | 2.87B | 3.03B | 1.56B | 3.65B | 4.53B | 5.36B | - | 8.36B | 6.48B | 6.83B | 8.05B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.13B | 10.54B | 10.79B | 12.07B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 558.00M | 637.00M | 559.00M | 493.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.31B | 6.66B | 7.01B | 8.47B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.37B | 941.00M | -6.39B | 1.94B |
| Net Income | - | - | 5.75B | 4.63B | 4.73B | 5.96B | 2.58B | 2.28B | 4.42B | 1.40B | 477.00M | 2.37B | 3.69B | 4.50B | - | 6.93B | 5.72B | 13.40B | 6.52B |
| Diluted EPS | 2.31 | 3.12 | 3.69 | 2.96 | 3.01 | 3.72 | 1.62 | 1.49 | 2.92 | 0.94 | 0.27 | 1.33 | 2.06 | 2.50 | - | 3.91 | 3.26 | 7.64 | 3.72 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | 2.26B | 2.30B | 2.44B | 2.42B | 2.74B | 2.89B | 2.74B | 2.84B | 2.94B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 39.71B | 42.42B | 52.58B | 60.57B | 60.28B | 67.23B | 42.94B | 41.21B | 41.25B | 52.67B | 76.25B | 67.17B | 67.89B | 72.55B | - | 74.44B | 73.21B | 81.41B | 86.71B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.22B | 22.67B | 23.66B | 26.00B |
| Cash & Equivalents | 521.19M | 2.46B | 4.11B | 8.81B | 3.65B | 6.81B | 10.80B | 3.48B | 4.06B | 5.00B | 18.62B | 9.41B | 3.84B | 3.86B | 6.84B | - | 9.88B | 6.90B | 7.62B | 8.52B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.17B | 6.57B | 6.19B | 6.49B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.22B | 6.57B | 6.92B | 7.93B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.53B | 34.39B | 33.51B | 33.94B |
| Current Liabilities | - | 9.10B | 11.59B | 13.05B | 17.26B | 15.48B | 13.28B | 9.51B | 10.47B | 9.19B | 6.66B | 8.91B | 9.01B | 10.86B | 11.91B | - | 15.49B | 13.84B | 14.16B | 16.50B |
| Long Term Debt | - | 9.49B | 8.71B | 11.27B | 12.52B | 12.04B | 18.09B | 3.39B | 3.39B | 5.87B | 20.68B | 27.21B | 19.36B | 16.66B | 18.53B | - | 14.52B | 13.60B | 12.62B | 9.90B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.72B | 15.63B | 15.02B | 13.86B |
| Total Equity | 14.05B | 17.78B | 17.48B | 23.14B | 22.68B | 24.44B | 26.72B | 25.17B | 21.53B | 21.21B | 20.54B | 30.90B | 30.52B | 31.09B | 32.78B | - | 36.69B | 38.60B | 47.66B | 52.13B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.99B | 1.99B | 1.99B | 2.00B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | 8.97B | 9.31B | 3.32B | 3.67B | 2.97B | 3.20B | 5.57B | 6.30B | 6.14B | 7.90B | - | 9.58B | 7.26B | 8.56B | 9.57B |
| Investing Cash Flow | - | -2.09B | -3.70B | -12.19B | 661.00M | -5.56B | -3.93B | -202.00M | 406.00M | -248.00M | -9.62B | -1.36B | -1.81B | -2.21B | - | -1.74B | -3.13B | -2.34B | -2.42B |
| Financing Cash Flow | - | -3.49B | 1.00B | -1.09B | -6.42B | 195.00M | -6.70B | -2.74B | -2.24B | 11.15B | -5.28B | -10.39B | -4.29B | -2.78B | - | -7.64B | -7.09B | -5.40B | -6.31B |
| Capital Expenditure | -1.66B | -1.29B | -1.09B | -1.02B | -1.49B | -1.79B | -1.15B | -1.08B | -1.11B | -1.12B | -1.14B | -1.39B | -1.64B | -2.18B | - | -1.78B | -2.20B | -2.21B | -2.17B |
| Free Cash Flow | - | - | - | - | 7.48B | 7.52B | 2.18B | 2.60B | 1.86B | 2.08B | 4.43B | 4.91B | 4.50B | 5.72B | - | 7.80B | 5.06B | 6.35B | 7.39B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 205.00M | -2.96B | 816.00M | 835.00M |
| Share Buybacks | 1.06B | 1.08B | 826.35M | 866.83M | 77.00M | 2.36B | 1.60B | 2.19B | 2.24B | 522.00M | 117.00M | 238.00M | 718.00M | 403.00M | 2.30B | 3.79B | 1.23B | 1.29B | 893.00M |
| Dividends Paid | 1.96B | 2.17B | 2.41B | 2.67B | 2.94B | 3.18B | 882.00M | 1.34B | 1.44B | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.1% | 55.2% | 55.4% | 56.4% |
| Operating Margin % | 17.7% | 19.3% | 20.3% | 17.3% | 7.6% | 7.1% | 10.9% | 12.8% | 14.1% | 14.5% | 5.7% | 11.9% | 14.2% | 15.5% | - | 19.2% | 16.2% | 16.3% | 18.2% |
| Net Margin % | - | - | 18.7% | 13.2% | 22.1% | 31.3% | 13.1% | 11.3% | 21.7% | 6.7% | 1.7% | 7.7% | 11.6% | 13.0% | - | 15.9% | 14.3% | 31.9% | 14.7% |
| ROE % | - | - | 24.8% | 20.4% | 19.3% | 22.3% | 10.2% | 10.6% | 20.9% | 6.8% | 1.5% | 7.8% | 11.9% | 13.7% | - | 18.9% | 14.8% | 28.1% | 12.5% |
| ROCE % | 15.0% | 18.5% | 15.8% | 14.1% | 3.6% | 2.5% | 6.4% | 8.5% | 8.9% | 6.6% | 2.3% | 6.3% | 7.9% | 8.8% | - | 14.2% | 10.9% | 10.1% | 11.5% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ABT
J&J Slipped On Its Report; Why It Bodes Well For Intuitive, Abbott, Others
Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.
Johnson & Johnson CFO Says This Drug Is Outperforming ‘Almost Any Launch’ in Recent Memory
Johnson & Johnson’s second-quarter earnings were met with a shrug on Wall Street, but one of the drugmaker’s top executives insists the most powerful growth drivers are just starting to pick up speed. J&J on Wednesday reported adjusted ea…
Reasons to Retain Abbott Stock in Your Portfolio for Now
ABT is banking on emerging-market pharmaceutical growth and innovation in Nutrition, but macro pressures and currency swings remain key challenges.
Abbott’s cancer diagnostics vision: ‘There’s always a hunger to make these tests better’
Jorge Garces, who joined Abbott to oversee scientific strategy for cancer diagnostics after it acquired Exact Sciences, discusses the future of the field.
Why This Group Of Medical Giants, Including Intuitive Surgical, Just Took A Tumble
Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.
Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?
ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.
ABT — Frequently Asked Questions
What is the current share price of Abbott Laboratories (ABT)?
As of 2026-07-15 16:51 PDT, Abbott Laboratories (ABT) trades at $89.27 on NYSE. Its 52-week range is $82.56 to $134.49.
What is the market capitalisation of ABT?
Abbott Laboratories (ABT) has a market capitalisation of $155.49B on NYSE.
What is the P/E ratio of ABT?
ABT trades at a trailing price-to-earnings (P/E) ratio of 25.01. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 2.95.
Does ABT pay a dividend?
Abbott Laboratories (ABT) currently offers a dividend yield of 2.86%.
What is the return on equity (ROE) of ABT?
ABT has a return on equity (ROE) of 12.33%. Its return on capital employed (ROCE) is 12.76%.
Is ABT a good stock to buy?
This page provides a data-driven analysis of Abbott Laboratories (ABT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.